Finished medicines exported to the EU enjoy EVFTA preferential rates — but only by meeting Protocol 1 origin rules. For pharmaceuticals, the origin story turns on one question: if the active ingredient (API) is imported from India or China, do tablets made in Viet Nam count as Vietnamese-originating?
1. Product rules for pharmaceuticals (HS Chapter 30)
Pharmaceuticals sit in HS Chapter 30; the Product Specific Rule in the Protocol 1 annex typically allows non-originating materials within a value cap, or requires a tariff-shift at a defined level. For the “imported API + excipients + packed in Viet Nam” formula, businesses must check two things: (a) whether the non-originating API value breaches the permitted ex-works threshold; (b) whether Vietnamese manufacturing meets “sufficient working or processing” — merely repacking or relabelling imported bulk does not count.
2. Pharma’s special feature: GMP and batch traceability
Unlike ordinary consumer goods, pharmaceuticals face strict quality regulation (GMP) — which doubles as an origin-proof advantage: GMP batch records fully document material sources, suppliers and norms — exactly the evidence EU customs needs under verification. Pharma businesses should “reuse” their existing GMP system to build per-product origin worksheets rather than constructing separate files. Note: APIs imported from countries with EU FTAs do not help — only Vietnamese- or EU-originating materials cumulate.
3. Practice: calculate before committing to a duty rate
The right workflow: (a) list APIs and excipients per product and identify each input’s origin; (b) compute the non-originating value ratio on ex-works price per product code — with an internal alert below the rule threshold; (c) state criterion “W” with the HS code on the origin declaration (pharma made from imported APIs is never “P”); (d) keep GMP batch records linked to export declarations. Pharma origin is arithmetic — get the calculation right and the duty preference follows naturally.
Conclusion
A “made in Vietnam” tablet earns EVFTA preference only when the origin calculation comes out positive. For pharma, GMP is both a quality licence and an origin-evidence vault — one system serving two purposes.
Frequently Asked Questions
Do Vietnamese-made medicines from imported APIs qualify for EVFTA preference?
They can, by meeting the HS Chapter 30 Product Specific Rule in the Protocol 1 annex: non-originating material value within the permitted cap and sufficient working or processing in Viet Nam.
Does merely repacking or relabelling imports count as sufficient processing?
Usually not. Repacking or relabelling imported bulk does not count as sufficient working or processing under EVFTA origin rules.
How does GMP help prove origin?
GMP batch records fully document material sources, suppliers and norms — exactly the origin evidence EU customs needs under verification. Reuse the GMP system for origin worksheets.
Which criterion goes on the declaration for pharma made from imported APIs?
Criterion W with the HS code — pharma made from imported APIs is never P (wholly obtained). A wrong criterion risks preference denial.
